ERBB4
Receptor tyrosine-protein kinase erbB-4
As of the edition of 20 October 2026, ERBB4 (receptor tyrosine-protein kinase erbB-4, UniProt Q15303) has 7 drugs tested at it and 10 companies on the list, 6 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q15303
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 14
- Disease areas
- Cancer; Lungs and airways; Digestive system; Skin and connective tissue; Hormones; Urinary and reproductive; Pregnancy and women's health; Nervous system
- Registered trials of its drugs
- 138
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Went quiet | 3 |
| Stopped | 3 |
| Total | 7 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Vandetanib | Marketed | Phase 3 | none listed |
| Poziotinib | Stopped | Phase 3 | none listed |
| BMS-690514 | Went quiet | Phase 2 | none listed |
| Tarloxotinib | Stopped | Phase 2 | none listed |
| JK07 | Stopped | Phase 2 | none listed |
| JNJ-26483327 | Went quiet | Phase 1 | none listed |
| KBP5209 | Went quiet | Phase 1 | none listed |
7 of 7 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 6 |
| Route B | 1 |
| Undetermined | 3 |
| Total on the list | 10 |
| Company | Route |
|---|---|
| Hanmi Pharmaceutical | Route A |
| Pathos AI | Route A |
| Zydus Worldwide DMCC | Route A |
The other 7 companies at ERBB4
In the product10 companies in all; 7 are not named here, and no score is.
See the 10 companies at ERBB4, ranked, with the facts behind eachRequest access. Nothing is shown until you do.